查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949614

DNA定序市場－全球產業規模、佔有率、趨勢、機會及預測（按產品類型、技術、應用、最終用戶、地區和競爭格局分類，2021-2031年）

DNA Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Technology, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球DNA定序市場預計將從2025年的155.6億美元成長到2031年的471.4億美元，複合年成長率為20.29%。

DNA定序是指利用先進的設備、耗材和生物資訊服務，對DNA分子內核苷酸鹼基序列進行精確識別，從而解碼遺傳訊息。市場成長的主要驅動力是定序成本的持續下降以及臨床上對個人化醫療日益成長的需求，尤其是在腫瘤學和罕見疾病診斷領域。這些核心促進因素不同於曇花一現的技術趨勢，並得益於基因組數據產生的龐大規模。例如，全球基因組與健康聯盟（Global Alliance for Genomics and Health）報告稱，到2024年，其合作夥伴網路將管理超過300萬個基因組，這表明目前在研究和臨床環境中利用的遺傳物質數量巨大。

市場概覽
預測期 2027-2031
市場規模：2025年 155.6億美元
市場規模：2031年 471.4億美元
複合年成長率：2026-2031年 20.29%
成長最快的細分市場 第三代定序
最大的市場 北美洲

然而，複雜的監管環境，特別是檢查室自建檢測（LDT）的監管，是限制市場擴張的一大障礙。這些診斷檢測的合規性和核准流程日益成長的不確定性，阻礙了其商業化進程，並可能延緩定序技術在臨床環境中的快速應用，儘管市場需求不斷成長。

市場促進因素

次世代定序平台技術的快速發展正在改變市場格局，降低了進入門檻，並促進了高通量分析。這一發展動能體現在新型台式定序儀的湧現和改進的化學方法上，這些方法降低了每千兆鹼基的成本，有效地推動了基因組分析能力向大型基因組中心以外的分散化。對這些創新技術的大量投資凸顯了它們在市場擴張中的關鍵作用。例如，Element Biosciences在2024年7月的D輪資金籌措公告中宣布，已籌集2.77億美元，用於加速其AVITI桌上型定序儀的商業化。這些進步創造了競爭格局，迫使現有企業進行創新，並透過提高數據品質和降低成本使用戶受益。 Illumina公司2024年第三季的核心營收達到11億美元，顯示全球對定序基礎設施的依賴程度依然很高，也反映了這個高科技產業的規模。

精準醫療和藥物基因體學的加速應用是推動市場成長的第二大主要因素，尤其是在腫瘤學領域。隨著定序日益融入臨床常規，對液態生物檢體和微量殘存疾病（MRD）監測的需求激增，從而實現了非侵入性腫瘤分析和個人化治療策略。癌症患者診斷檢測量的激增也推動了這項轉變。例如，Natera公司在2024年11月發布的2024年第三季財報中報告稱，其處理了約137,100例癌症檢測，較去年同期成長54%。這種快速應用表明，臨床醫生越來越依賴基因組數據來制定治療決策，而定序也從研究工具轉變為複雜疾病管理的關鍵標準。

市場挑戰

全球DNA定序市場面臨的主要障礙之一是實驗室自建檢測（LDT）監管架構日益複雜。這種日益嚴格的審查造成了不確定性，迫使臨床檢查室將大量資源從創新轉移到合規性。隨著監管機構尋求將這些檢測重新歸類​​為醫療設備，上市前審查和品質系統標準相關的預期成本和行政負擔構成了進入障礙。因此，實驗室不願投資新型定序技術或擴展其檢測項目，直接阻礙了先進基因組學應用的商業性化推廣。

監管瓶頸限制了市場成長，尤其是在細分診斷領域，迫使服務提供者縮減服務規模。遵守嚴格的核准通訊協定帶來的財務負擔往往超過了用於檢測罕見疾病的低通量檢測的獲利潛力。根據診斷和實驗室醫學協會 (ADLM) 2024 年的一項調查，超過 50% 的臨床檢查室正在考慮停止某些實驗室自建檢測項目，原因是 FDA 新監管規則帶來的營運和財務負擔。診斷選擇的減少限制了患者獲得基於定序的療法的機會，導致對定序設備和耗材的整體需求下降。

市場趨勢

第三代長讀長定序技術的興起正在改變市場格局，它能夠分析短讀長定序平台難以處理的複雜基因組區域。這些系統可以即時讀取生物DNA分子，並準確地識別結構變異和表觀遺傳修飾，且不存在擴增偏差。這項優勢正推動其在臨床研究和應用市場中的廣泛應用，因為在這些領域，完整的基因組可視性對於研究大規模遺傳變異至關重要。例如，牛津奈米孔技術公司在其2025年3月發布的「截至2024年12月31日止年度財務業績」中報告稱，由於其平台應用範圍的擴大，公司收入達到1.832億英鎊（不計外匯波動影響，成長11.1%）。

同時，將人工智慧 (AI) 和機器學習 (ML) 整合到基因組分析中，對於解讀現代定序儀產生的大量數據至關重要。隨著主要瓶頸從數據生成轉向數據分析，人工智慧模型正被用於加速變異檢測和功能預測。這些演算法使研究人員能夠更快地檢測到致病突變，從而顯著提升基因組數據在精準醫療中的價值。為了體現這一趨勢，10x Genomics 在其於 2025 年 2 月發布的“2024 年第四季度及全年財務業績”中宣布啟動“十億細胞項目”，旨在構建一個包含十億個細胞的資料集，以推動人工智慧模型開發的快速發展。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球DNA定序市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（設備、耗材、服務）
    • 依技術分類（桑格定序、次世代定序(NGS)、第三代定序、其他）
    • 按應用領域（診斷、調查、個人化醫療、刑事鑑定等）
    • 按最終用戶（醫院/醫療機構、學術研究機構、製藥/生技公司、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美DNA定序市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球DNA定序市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • QIAGEN NV
  • Merck KGaA
  • Macrogen, Inc.
  • PerkinElmer, Inc.
  • Eurofins Scientific Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27580

The Global DNA Sequencing Market is projected to expand from USD 15.56 Billion in 2025 to USD 47.14 Billion by 2031, registering a CAGR of 20.29%. DNA sequencing is characterized as the exact identification of the nucleotide base order within a DNA molecule, achieved through advanced instrumentation, consumables, and bioinformatics services that decode genetic data. The market's upward trajectory is chiefly driven by the continuous decline in sequencing costs and the rising clinical requirement for personalized medicine, specifically within oncology and rare disease diagnostics. These core drivers differ from temporary technological trends and are bolstered by the immense scale of genomic data production; for instance, the Global Alliance for Genomics and Health reported that in 2024, their partner network managed over 3,000,000 genomes, demonstrating the significant volume of genetic material currently employed in research and clinical settings.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 15.56 Billion
Market Size 2031USD 47.14 Billion
CAGR 2026-203120.29%
Fastest Growing SegmentThird-Generation Sequencing
Largest MarketNorth America

However, a major obstacle limiting wider market growth is the increasingly intricate regulatory landscape, particularly regarding the supervision of Laboratory Developed Tests (LDTs). The escalating uncertainty regarding compliance and approval processes for these diagnostic assays forms a commercialization bottleneck, which could potentially delay the swift integration of sequencing technologies into clinical environments despite rising demand.

Market Driver

Swift technological progress in Next-Generation Sequencing Platforms is transforming the market structure by reducing entry barriers and facilitating high-throughput analysis. This momentum is defined by the arrival of new benchtop sequencers and chemistry upgrades that lower the cost per gigabase, effectively decentralizing genomic capabilities beyond large-scale genome centers. The significant investment in these disruptive technologies highlights their essential role in market expansion; for example, Element Biosciences announced in its 'Series D Funding Announcement' in July 2024 that it raised $277 million to hasten the commercial launch of its AVITI benchtop sequencer. Such developments create a competitive landscape that forces incumbent companies to innovate, benefiting users through enhanced data quality and lower costs. To demonstrate the scale of this high-tech sector, Illumina reported third-quarter core revenue of $1.1 billion in 2024, indicating continued global dependence on sequencing infrastructure.

The hastened adoption of Precision Medicine and Pharmacogenomics acts as the second major catalyst for market growth, especially within oncology. As sequencing becomes embedded in clinical routines, there is a surge in demand for liquid biopsy and minimal residual disease (MRD) monitoring, enabling non-invasive tumor profiling and tailored treatment strategies. This shift is substantiated by the rapidly increasing volume of diagnostic tests for cancer patients. For instance, Natera reported in its 'Third Quarter 2024 Financial Results' in November 2024 that it processed roughly 137,100 oncology tests, a 54% rise over the same period the previous year. This swift adoption illustrates how clinicians increasingly depend on genomic data for therapeutic decisions, transforming sequencing from a research instrument into a critical standard of care for managing complex conditions.

Market Challenge

The central obstacle hindering the Global DNA Sequencing Market is the progressively complex regulatory framework governing Laboratory Developed Tests (LDTs). This intensified scrutiny generates uncertainty, compelling clinical laboratories to redirect essential resources from innovation toward compliance efforts. As regulators aim to reclassify these assays as medical devices, the projected costs and administrative workloads linked to premarket reviews and quality system standards become exclusionary. Consequently, laboratories are less inclined to invest in novel sequencing technologies or broaden their testing menus, which directly suppresses the commercial uptake of advanced genomic applications.

This regulatory bottleneck curbs market growth by forcing service providers to reduce their offerings, specifically for niche diagnostics. The financial burden of adhering to strict approval protocols often exceeds the revenue potential of low-volume tests employed in rare disease detection. According to a 2024 survey by the Association for Diagnostics and Laboratory Medicine, over 50% of clinical laboratories intended to stop offering certain laboratory-developed tests due to the operational and financial strains resulting from the new FDA oversight rule. This decrease in available diagnostic options restricts patient access to sequencing-based treatments, thereby lowering the total demand for sequencing instruments and consumables.

Market Trends

The rise of Third-Generation Long-Read Sequencing Technologies is transforming the market by addressing complex genomic regions that short-read platforms struggle to analyze. These systems read native DNA molecules in real-time, allowing for the accurate identification of structural variants and epigenetic modifications without the bias caused by amplification. This ability is fueling growing adoption in clinical research and applied markets, where complete genomic visibility is essential for studying large-scale genetic variation. For example, Oxford Nanopore Technologies reported in its 'Annual results for the year ended 31 December 2024' released in March 2025 that revenue reached £183.2 million, an 11.1% increase on a constant currency basis, attributed to the wider use of its platform.

Concurrently, the integration of Artificial Intelligence and Machine Learning for Genomic Analysis is proving indispensable for interpreting the massive amounts of data produced by modern sequencers. As the primary bottleneck shifts from data generation to analysis, AI-powered models are being utilized to speed up variant calling and functional prediction. These algorithms enable researchers to detect disease-causing mutations more rapidly, greatly enhancing the value of genomic data for precision medicine. Highlighting this trend, 10x Genomics announced in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 the initiation of the Billion Cells Project, aiming to create a one billion cell dataset specifically to drive rapid advancements in AI model development.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Merck KGaA
  • Macrogen, Inc.
  • PerkinElmer, Inc.
  • Eurofins Scientific Limited

Report Scope

In this report, the Global DNA Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Sequencing Market, By Product Type

  • Instruments
  • Consumables
  • Services

DNA Sequencing Market, By Technology

  • Sanger Sequencing
  • Next-Generation Sequencing (NGS)
  • Third-Generation Sequencing
  • Others

DNA Sequencing Market, By Application

  • Diagnostics
  • Research
  • Personalized Medicine
  • Forensic Testing
  • Others

DNA Sequencing Market, By End User

  • Hospitals and Healthcare Organizations
  • Academics and Research Institutions
  • Pharmaceutical and Biotechnology Companies
  • Others

DNA Sequencing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Sequencing Market.

Available Customizations:

Global DNA Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Sequencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Instruments, Consumables, Services)
    • 5.2.2. By Technology (Sanger Sequencing, Next-Generation Sequencing (NGS), Third-Generation Sequencing, Others)
    • 5.2.3. By Application (Diagnostics, Research, Personalized Medicine, Forensic Testing, Others)
    • 5.2.4. By End User (Hospitals and Healthcare Organizations, Academics and Research Institutions, Pharmaceutical and Biotechnology Companies, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America DNA Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States DNA Sequencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada DNA Sequencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico DNA Sequencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe DNA Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany DNA Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. France DNA Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom DNA Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy DNA Sequencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain DNA Sequencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia Pacific DNA Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China DNA Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India DNA Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan DNA Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea DNA Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia DNA Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Middle East & Africa DNA Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia DNA Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE DNA Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa DNA Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. South America DNA Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil DNA Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia DNA Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina DNA Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global DNA Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. Illumina, Inc.
  • 15.6. QIAGEN N.V.
  • 15.7. Merck KGaA
  • 15.8. Macrogen, Inc.
  • 15.9. PerkinElmer, Inc.
  • 15.10. Eurofins Scientific Limited

16. Strategic Recommendations

17. About Us & Disclaimer